No retraction, correction or concern found when last checked on Oct 31, 2026.
Highly pathogenic coronavirus N protein aggravates inflammation by MASP-2-mediated lectin complement pathway overactivation
Ting Gao, Lin Zhu, Hainan Liu and 29 more
Signal Transduction and Targeted Therapy · 2022 · Case report · CC BY
doi:10.1101/2020.03.29.20041962
Abstract
Excessive inflammatory responses contribute to the pathogenesis and lethality of highly pathogenic human coronaviruses, but the underlying mechanism remains unclear. In this study, the N proteins of highly pathogenic human coronaviruses, including severe acute respiratory syndrome coronavirus (SARS-CoV), middle east respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), were found to bind MASP-2, a key serine protease in the lectin pathway of complement activation, resulting in excessive complement activation by potentiating MBL-dependent MASP-2 activation, and the deposition of MASP-2, C4b, activated C3 and C5b-9. Aggravated inflammatory lung injury was observed in mice infected with adenovirus expressing the N protein. Complement hyperactivation was also observed in SARS-CoV-2-infected patients. Either blocking the N protein:MASP-2 interaction, MASP-2 depletion or suppressing complement activation can significantly alleviate N protein-induced complement hyperactivation and lung injury in vitro and in vivo. Altogether, these data suggested that complement suppression may represent a novel therapeutic approach for pneumonia induced by these highly pathogenic coronaviruses.
Cited by papers we hold 8
- Complement Levels at Admission Reflecting Progression to Severe Acute Kidney Injury (AKI) in Coronavirus Disease 2019 (COVID-19): A Multicenter Prospective Cohort Study · 2022Not checked
- Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection · 2021No notice
- Role of IgG against N-protein of SARS-CoV2 in COVID19 clinical outcomes · 2021Not checked
- Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock—A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study) · 2021Not checked
- COVID-19 Mechanisms in the Human Body—What We Know So Far · 2021Not checked
- Lectin Pathway Mediates Complement Activation by SARS-CoV-2 Proteins · 2021No notice
- Endothelium Infection and Dysregulation by SARS-CoV-2: Evidence and Caveats in COVID-19 · 2020No notice
- I mmunosenescence and Inflammaging: Risk Factors of Severe COVID-19 in Older People · 2020No notice
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.